When searching for FtsZ inhibitors on PubMed, there are 187 hits. When narrowing down the search looking for clinical trials only, there are none. Taxis Pharmaceuticals obtained QIDP status for its candidate drug TXA-709 in late 2016 and it is
Continue reading TXA-709 – New Kid on the Block → Like this: Like Loading...
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged antibiotic blog, Brilacidin, cefdinir, ceftaroline, ceftibiprole, Cellceutix, Cempra, Cubicin, dalbavancin, Dalvance, daptomycin, Debio-1450, Debiopharm, efflux inhibitor, FabI inhibitor, FDA, FtsZ inhibitor, Harald Reinhart, linezolid, LpxC, macrolide, MRSA, MRSA drugs, MSSA, novel MoA, Omnicef, Orbactiv, oritavancin, POL-7080, QIDP, Sivextro, solithromycin, synergy, Taxis Pharmaceuticals, tedizolid, Teflaro, telavancin, tetracycline, TMP/SMX, TXA-707, TXA-709, vancomycin, Vibativ, Zyvox |
Just before the November 4th AMDAC on solithromycin, we are being treated to a very fine piece of study write-up. Of course, we are speaking of the File paper on the SOLITAIRE-IV trial, and what a fine piece of crafty
Continue reading Solithromycin SOLITAIRE-IV: So-So Results for a So-So Drug → Like this: Like Loading...
Posted in QIDP Antibiotics, Recent Literature, The News, The Viewpoint |
Tagged AIDAC, AMDAC, antibiotic blog, Avelox, CABP Guidance, Cempra, delta, drotrecogin, efficacy criteria, efficacy margins, FDA, FDA vs EU guidelines, File, Harald Reinhart, IV site reactions, IV/PO, ketolide, loading dose, macrolide, moxifloxacin, NI, non-inferiority, PORT score, SOLITAIRE-IV, SOLITAIRE-ORAL, tigecycline, Tygacil, Xigris |
Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these
Continue reading QIDP Antibiotics – 2015 Year-End Update → Like this: Like Loading...
Posted in QIDP Antibiotics, The News |
Tagged ABSSSI, Allphase Pharma Consulting, aminoglycosides, amphotericin B, antibiotic blog, azole, Beta-lactam, BL/BLI combination, bronchiectasis, CABP, ceftazidime/avibactam / Avycaz, ceftolozane/tazobactam / Zerbaxa, cystic fibrosis, dalbavancin / Dalvance, defensin-mimetic, DHFR inhibitor, enfumafungin, FabI inhibitor, fluoroquinolones, Fusidic Acid, GC, Harald Reinhart, isavuconazole / Cresemba, ketolide, macrolide, MoA, nikkomycin, NTM, oritavancin / Orbactiv, oxazolidinone, pleuromutilin, sulfonamide, tedizolid / Sivextro, tetracycline, topisomerase II-inhibitor, vancomycin, VAP |
Any FDA meeting is a high-stakes game for industry: One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective. At other times, simple issues seem to create
Continue reading The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates? → Like this: Like Loading...
Posted in The News, The Viewpoint |
Tagged ABECB-COPD, ABS, acute exacerbation of chronic bronchitis, AECB, AIDAC, Allphase Pharma Consulting, AMDAC, American Thoracic Society, amoxicillin, antibiotic blog, ATS, AUA, Avelox, Bayer, C. difficile colitis, CDI, CFS, chronic fatigue syndrome, Cipro, ciprofloxacin, FAERS, FDA, FDA adverse event reporting system, FDA Advisory Committee Anti-Infectives, Fluoroquinolone-associated disability, fluoroquinolones, fosfomycin, FQAD, Harald Reinhart, IDSA, Johnson & Johnson, Levaquin, levofloxacin, macrolide, moxifloxacin, nitrofurantoin, penicillin allergy, QTc, QTc prolongation, sinusitis, Stevens-Johnson syndrome, TMP/SMX, trimethoprim-sulfamethoxazole, urinary tract infection, uUTI |
Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg . In
Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1) → Like this: Like Loading...
Posted in Did you know...?, QIDP Antibiotics, Recent Literature, The News |
Tagged aminoglycoside, antibiotic blog, AZ-0914, azithromycin, aztreonam, Beta-lactam, CDC, cefixime, cefodizime, cefotaxime, cefoxitin, Ceftizox, ceftizoxime, ceftriaxone, cefuroxime, CEM-101, Cipro, ciprofloxacin, Claforan, delafloxacin, erythromycin, fleroxacin, fluoroquinolones, gentamicin, GISP database, gonococcal resistance, gonorrhea, macrolide, Mefoxitin, N. gonorrhoeae, Neisser, netilmicin, norfloxacin, ofloxacin, Omniflox, pefloxacin, Pfizer, Public Health Canada, Rocephin, sisomicin, solithromycin, spectinomycin, STD recommendations, Suprax, temafloxacin, Trobicin, Zinacef, Zithromax |